fluoxetine has been researched along with Abnormalities, Drug-Induced in 32 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to examine whether there is an increased risk for major malformations following the use of fluoxetine during the first trimester of pregnancy." | 8.80 | Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. ( Addis, A; Koren, G, 2000) |
| "To investigate the safety of fluoxetine use during pregnancy, and to better understand the relationship between maternal fluoxetine use during the first trimester and congenital malformations in infants." | 4.95 | Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies. ( Gao, SY; Ji, C; Liu, CX; Shen, ZQ; Wu, QJ; Xu, X; Zhang, TN; Zhao, YH, 2017) |
| "The apparent increased risk of fetal cardiac malformations associated with maternal use of fluoxetine has recently been shown also in depressed women who deferred SSRI therapy in pregnancy, and therefore most probably reflects an ascertainment bias." | 4.89 | The fetal safety of fluoxetine: a systematic review and meta-analysis. ( Frankel, Z; Koren, G; Moretti, M; Pupco, A; Riggin, L, 2013) |
| "This study was designed to examine whether there is an increased risk for major malformations following the use of fluoxetine during the first trimester of pregnancy." | 4.80 | Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. ( Addis, A; Koren, G, 2000) |
| "Among the significant associations found, an association between maternal use of fluoxetine and infantile hypertrophic pyloric stenosis (IHPS) was of particular interest." | 3.76 | Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study. ( Bakker, MK; de Jong-Van den Berg, LT; De Walle, HE; Wilffert, B, 2010) |
| " We present the occurrence of Goldenhar syndrome in an infant born to a woman with a history of prenatal Fluoxetine ingestion throughout her pregnancy." | 3.76 | Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence? ( Awwad, J; Farra, C; Majdalani, M; Mikati, M; Yazbeck, N; Yunis, K, 2010) |
| " The low birth weight infants had been exposed to relatively high doses of fluoxetine (40-80 mg/d) throughout pregnancy." | 3.72 | Birth outcomes after prenatal exposure to antidepressant medication. ( Altshuler, L; Haynes, D; Hendrick, V; Hwang, S; Smith, LM; Suri, R, 2003) |
| "Prospectively identified fluoxetine-exposed pregnancies were evaluated to determine whether fluoxetine, a serotonin reuptake inhibitor commonly used for the treatment of depression and obsessive-compulsive disorder, might be associated with neonatal complications after maternal fluoxetine exposure during the third trimester through delivery." | 3.69 | Effects of third trimester fluoxetine exposure on the newborn. ( Goldstein, DJ, 1995) |
| "The rate of spontaneous pregnancy loss did not differ significantly between the women treated with fluoxetine and the control women (10." | 3.69 | Birth outcomes in pregnant women taking fluoxetine. ( Chambers, CD; Dick, LM; Felix, RJ; Johnson, KA; Jones, KL, 1996) |
| "We evaluated outcomes of all pregnancies identified prospectively with confirmed first-trimester fluoxetine exposure contained in the Eli Lilly and Company worldwide fluoxetine pregnancy registry." | 3.69 | Effects of first-trimester fluoxetine exposure on the newborn. ( Corbin, LA; Goldstein, DJ; Sundell, KL, 1997) |
| "Fluoxetine was associated with an increased risk of isolated ventricular septal defects (adjusted OR 2." | 1.37 | Selective serotonin reuptake inhibitors and risk for major congenital anomalies. ( Artama, M; Gissler, M; Malm, H; Ritvanen, A, 2011) |
| "Only sertraline was capable of causing developmental toxicity in tadpoles at environmentally relevant concentrations." | 1.35 | Growth and development of tadpoles (Xenopus laevis) exposed to selective serotonin reuptake inhibitors, fluoxetine and sertraline, throughout metamorphosis. ( Armbrust, KL; Black, MC; Conners, DE; Kwon, JW; Rogers, ED, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (40.63) | 18.2507 |
| 2000's | 7 (21.88) | 29.6817 |
| 2010's | 12 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, SY | 1 |
| Wu, QJ | 1 |
| Zhang, TN | 1 |
| Shen, ZQ | 1 |
| Liu, CX | 1 |
| Xu, X | 1 |
| Ji, C | 1 |
| Zhao, YH | 1 |
| Riggin, L | 1 |
| Frankel, Z | 1 |
| Moretti, M | 1 |
| Pupco, A | 2 |
| Koren, G | 5 |
| Diav-Citrin, O | 1 |
| Shechtman, S | 1 |
| Weinbaum, D | 1 |
| Wajnberg, R | 1 |
| Avgil, M | 1 |
| Di Gianantonio, E | 1 |
| Clementi, M | 1 |
| Weber-Schoendorfer, C | 1 |
| Schaefer, C | 1 |
| Ornoy, A | 1 |
| Conners, DE | 1 |
| Rogers, ED | 1 |
| Armbrust, KL | 1 |
| Kwon, JW | 1 |
| Black, MC | 1 |
| Bakker, MK | 1 |
| De Walle, HE | 1 |
| Wilffert, B | 1 |
| de Jong-Van den Berg, LT | 1 |
| Farra, C | 1 |
| Yunis, K | 1 |
| Mikati, M | 1 |
| Yazbeck, N | 1 |
| Majdalani, M | 1 |
| Awwad, J | 1 |
| Tuccori, M | 1 |
| Montagnani, S | 1 |
| Testi, A | 1 |
| Ruggiero, E | 1 |
| Mantarro, S | 1 |
| Scollo, C | 1 |
| Pergola, A | 1 |
| Fornai, M | 1 |
| Antonioli, L | 1 |
| Colucci, R | 1 |
| Corona, T | 1 |
| Blandizzi, C | 1 |
| Foster, HR | 1 |
| Burton, GA | 1 |
| Basu, N | 1 |
| Werner, EE | 1 |
| Chambers, CD | 2 |
| Malm, H | 1 |
| Artama, M | 1 |
| Gissler, M | 1 |
| Ritvanen, A | 1 |
| Bozzo, P | 1 |
| Spinelli, M | 1 |
| Puryear, LJ | 1 |
| Einarson, A | 1 |
| Petersen, I | 1 |
| Gilbert, R | 1 |
| Evans, S | 1 |
| Nazareth, I | 1 |
| Hendrick, V | 1 |
| Smith, LM | 1 |
| Suri, R | 1 |
| Hwang, S | 1 |
| Haynes, D | 1 |
| Altshuler, L | 1 |
| Hines, RN | 1 |
| Adams, J | 1 |
| Buck, GM | 1 |
| Faber, W | 1 |
| Holson, JF | 1 |
| Jacobson, SW | 1 |
| Keszler, M | 1 |
| McMartin, K | 1 |
| Segraves, RT | 1 |
| Singer, LT | 1 |
| Sipes, IG | 1 |
| Williams, PL | 1 |
| Goldstein, DJ | 4 |
| Marvel, DE | 1 |
| Johnson, KA | 1 |
| Dick, LM | 1 |
| Felix, RJ | 1 |
| Jones, KL | 1 |
| Robert, E | 1 |
| Nulman, I | 1 |
| Johnson, GL | 1 |
| Cohen, LS | 2 |
| Rosenbaum, JF | 1 |
| Sundell, KL | 2 |
| Corbin, LA | 2 |
| Gupta, S | 1 |
| Rangwani, S | 1 |
| Addis, A | 1 |
| Calil, HM | 1 |
| Nonacs, R | 1 |
| Shuey, DL | 1 |
| Sadler, TW | 1 |
| Lauder, JM | 1 |
| Shader, RI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Transcranial Direct Current Stimulation (tDCS) for Depression in Pregnancy: A Pilot Study[NCT02116127] | 20 participants (Actual) | Interventional | 2014-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for fluoxetine and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetin | 2017 |
The fetal safety of fluoxetine: a systematic review and meta-analysis.
Topics: Abnormalities, Drug-Induced; Case-Control Studies; Cohort Studies; Depression; Female; Fluoxetine; H | 2013 |
Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update.
Topics: Abnormalities, Drug-Induced; Cardiovascular Abnormalities; Citalopram; Depression; Female; Fluoxetin | 2010 |
NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine.
Topics: Abnormalities, Drug-Induced; Animals; Fluoxetine; Humans; Infant, Newborn; Infant, Newborn, Diseases | 2004 |
The safety of fluoxetine during pregnancy and lactation.
Topics: Abnormalities, Drug-Induced; Animals; Antidepressive Agents, Second-Generation; Breast Feeding; Fema | 1996 |
Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; E | 2000 |
Fluoxetine: a suitable long-term treatment.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents, Tricyclic; Chemistry, Pharmaceutical; Child; Chi | 2001 |
Depression during pregnancy: diagnosis and treatment options.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depress | 2002 |
24 other studies available for fluoxetine and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
"Prozac Baby" - 25 years of motherisk research into SSRIs and alcohol in pregnancy.
Topics: Abnormalities, Drug-Induced; Alcohol Drinking; Antidepressive Agents, Second-Generation; Depression; | 2014 |
Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.
Topics: Abnormalities, Drug-Induced; Abortion, Induced; Adult; Antidepressive Agents, Second-Generation; Bir | 2008 |
Growth and development of tadpoles (Xenopus laevis) exposed to selective serotonin reuptake inhibitors, fluoxetine and sertraline, throughout metamorphosis.
Topics: Abnormalities, Drug-Induced; Animals; Dose-Response Relationship, Drug; Fluoxetine; Larva; Metamorph | 2009 |
Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study.
Topics: Abnormalities, Drug-Induced; Confidence Intervals; Female; Fluoxetine; Humans; Infant; Infant, Newbo | 2010 |
Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence?
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents, Second-Generation; Female; Fluoxetine; Go | 2010 |
Chronic exposure to fluoxetine (Prozac) causes developmental delays in Rana pipiens larvae.
Topics: Abnormalities, Drug-Induced; Animals; Dose-Response Relationship, Drug; Fluoxetine; Larva; Rana pipi | 2010 |
Value of the small cohort study including a physical examination for minor structural defects in identifying new human teratogens.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antidepressive Agents; Arthritis, Rheumatoid; Carbamaz | 2011 |
Selective serotonin reuptake inhibitors and risk for major congenital anomalies.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Alcohol Drinking; Female; Finland; Fluoxetine; Heart | 2011 |
Selective serotonin reuptake inhibitors and risk for major congenital anomalies.
Topics: Abnormalities, Drug-Induced; Female; Fluoxetine; Humans; Paroxetine; Pregnancy; Selective Serotonin | 2011 |
Selective serotonin reuptake inhibitors and risk for major congenital anomalies.
Topics: Abnormalities, Drug-Induced; Female; Fluoxetine; Humans; Paroxetine; Pregnancy; Selective Serotonin | 2011 |
Selective serotonin reuptake inhibitors and risk for major congenital anomalies.
Topics: Abnormalities, Drug-Induced; Female; Fluoxetine; Humans; Paroxetine; Pregnancy; Selective Serotonin | 2012 |
Birth outcomes after prenatal exposure to antidepressant medication.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; | 2003 |
Psychotropic medications during pregnancy: risk to the fetus.
Topics: Abnormalities, Drug-Induced; Female; Fluoxetine; Humans; Pregnancy; Pregnancy Complications; Pregnan | 1993 |
Effects of third trimester fluoxetine exposure on the newborn.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; D | 1995 |
Birth outcomes in pregnant women taking fluoxetine.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Affective Symptoms; Birth Weight; Case-Co | 1996 |
Treating depression in pregnancy.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents; Depression; Female; Fluoxetine; Humans; Infant, | 1996 |
Birth outcomes in pregnant women taking fluoxetine.
Topics: Abnormalities, Drug-Induced; Adult; Clinical Trials as Topic; Depression; Female; Fluoxetine; Humans | 1997 |
Birth outcomes in pregnant women taking fluoxetine.
Topics: Abnormalities, Drug-Induced; Female; Fluoxetine; Humans; Infant, Newborn; Infant, Newborn, Diseases; | 1997 |
Birth outcomes in pregnant women taking fluoxetine.
Topics: Abnormalities, Drug-Induced; Female; Fluoxetine; Humans; Infant, Newborn; Infant, Newborn, Diseases; | 1997 |
Effects of first-trimester fluoxetine exposure on the newborn.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adverse Drug Reaction Reporting Systems; Antidep | 1997 |
SSRIs in pregnancy.
Topics: Abnormalities, Drug-Induced; Animals; Depressive Disorder; Female; Fluoxetine; Humans; Infant, Newbo | 1998 |
Serotonin reuptake inhibitor antidepressants and pregnancy: many unanswered questions.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents, Second-Generation; Child; Child, Preschool; Clin | 1999 |
Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors.
Topics: 1-Naphthylamine; Abnormalities, Drug-Induced; Amitriptyline; Animals; Cell Death; Cell Division; Epi | 1992 |
Does continuous use of fluoxetine during the first trimester of pregnancy present a high risk for malformation or abnormal development to the exposed fetus?
Topics: Abnormalities, Drug-Induced; Female; Fluoxetine; Humans; Pregnancy; Pregnancy Outcome; Pregnancy Tri | 1992 |